Table 2Excluded GLP-1 trials

First author and yearReason for exclusion
Exenatide trials
Bunck 2007 55Participants were on metformin monotherapy. In addition, it is not clear from the abstract whether they remained on metformin.
Buse 2004 56Participants had failed on sulphonylurea monotherapy.
Trescoli-Serano 2005 57Abstract only and few details. Doesn’t say whether oral agents continued
Kim 2007 (exenatide LAR) 47No details yet and not licensed

From: 2, The glucagon-like peptide-1 analogue; exenatide

Cover of Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)
Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement) [Internet].
NICE Clinical Guidelines, No. 87S.
Waugh N, Cummins E, Royle P, et al.
Copyright © 2009, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.